THRA and DIO2 mutations are unlikely to be a common cause of increased bone mineral density in euthyroid post-menopausal women

European Journal of Endocrinology

Volumn 170, Issue 4, 2014, Pages 637-644

  Gogakos, Apostolos ^a   Logan, John G ^a   Waung, Julian A ^a   Bassett, J H Duncan ^a   Glüer, Claus C ^b   Reid, David M ^c   Felsenberg, Dieter ^d   Roux, Christian ^e   Eastell, Richard ^f   Williams, Graham R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d HUMBOLDT UNIVERSITY   (Germany)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',5' TRIIODOTHYRONINE; PARATHYROID HORMONE; THYROID HORMONE RECEPTOR ALPHA; THYROTROPIN; THYROXINE; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; COHORT ANALYSIS; CONTROLLED STUDY; DIO2 GENE; EUROPE; EXON; FEMALE; FRACTURE; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; INTRON; LIOTHYRONINE BLOOD LEVEL; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST; THRA GENE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; VITAMIN BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY; COHORT STUDIES; FEMALE; GENES, ERBA; GENOTYPE; HUMANS; IODIDE PEROXIDASE; MIDDLE AGED; MUTATION; PARATHYROID HORMONE; POSTMENOPAUSE; PROSPECTIVE STUDIES; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE; VITAMIN D;

EID: 84899482519     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-1009     Document Type: Article

References (35)

1. Waung JA, Bassett JH & Williams GR. Thyroid hormone metabolism in skeletal development and adult bone maintenance. Trends in Endocrinology and Metabolism 2012 23 155-162. (doi:10.1016/j.tem.2011.11.002)
2. Vestergaard P & Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16, 249 patients. Thyroid 2002 12 411-419. (doi:10.1089/105072502760043503)
3. Bianco AC & Kim BW. Deiodinases: implications of the local control of thyroid hormone action. Journal of Clinical Investigation 2006 116 2571-2579. (doi:10.1172/JCI29812)
4. Cheng SY, Leonard JL & Davis PJ. Molecular aspects of thyroid hormone actions. Endocrine Reviews 2010 31 139-170. (doi:10.1210/er.2009-0007)
5. Refetoff S, De Wind LT & De Groot LJ. Familial syndrome combining deaf-mutism, stuppled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone. Journal of Clinical Endocrinology and Metabolism 1967 27 279-294. (doi:10.1210/jcem-27-2-279)
6. Sakurai A, Takeda K, Ain K, Ceccarelli P, Nakai A, Seino S, Bell GI, Refetoff S & De Groot LJ. Generalized resistance to thyroid hormone associated with a mutation in the ligand-binding domain of the human thyroid hormone receptor β. PNAS 1989 86 8977-8981. (doi:10.1073/pnas.86.22.8977)
7. Bochukova E, Schoenmakers N, Agostini M, Schoenmakers E, Rajanayagam O, Keogh JM, Henning E, Reinemund J, Gevers E, Sarri M et al. A mutation in the thyroid hormone receptor α gene. New England Journal of Medicine 2012 366 243-249. (doi:10.1056/NEJMoa1110296)
8. Moran C, Schoenmakers N, Agostini M, Schoenmakers E, Offiah A, Kydd A, Kahaly G, Mohr-Kahaly S, Rajanayagam O, Lyons G et al. An adult female with resistance to thyroid hormone mediated by defective thyroid hormone receptor α. Journal of Clinical Endocrinology and Metabolism 2013 98 4254-4261. (doi:10.1210/jc.2013-2215)
9. Van Mullem A, Van Heerebeek R, Chrysis D, Visser E, Medici M, Andrikoula M, Tsatsoulis A, Peeters R & Visser TJ. Clinical phenotype and mutant TRα1. New England Journal of Medicine 2012 366 1451-1453. (doi:10.1056/NEJMc1113940)
10. Van Mullem AA, Chrysis D, Eythimiadou A, Chroni E, Tsatsoulis A, De Rijke YB, Visser WE, Visser TJ & Peeters RP. Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor: consequences of LT4 treatment. Journal of Clinical Endocrinology and Metabolism 2013 98 3029-3038. (doi:10.1210/jc. 2013-1050)
11. Dumitrescu AM & Refetoff S. The syndromes of reduced sensitivity to thyroid hormone. Biochimica et Biophysica Acta 2012 1830 3987-4003. (doi:10.1016/j.bbagen. 2012.08.005)
12. O'Shea PJ, Bassett JH, Cheng SY & Williams GR. Characterization of skeletal phenotypes of TRα1 and TRβ mutant mice: implications for tissue thyroid status and T3 target gene expression. Nuclear Receptor Signaling 2006 4 e011. (doi:10.1621/nrs.04011)
13. O'Shea PJ, Bassett JH, Sriskantharajah S, Ying H, Cheng SY & Williams GR. Contrasting skeletal phenotypes in mice with an identical mutation targeted to thyroid hormone receptor α1 or β. Molecular Endocrinology 2005 19 3045-3059. (doi:10.1210/me.2005-0224)
14. Bassett JH, Nordstrom K, Boyde A, Howell PG, Kelly S, Vennstrom B & Williams GR. Thyroid status during skeletal development determines adult bone structure and mineralization. Molecular Endocrinology 2007 21 1893-1904. (doi:10.1210/me.2007-0157)
15. Tinnikov A, Nordstrom K, Thoren P, Kindblom JM, Malin S, Rozell B, Adams M, Rajanayagam O, Pettersson S, Ohlsson C et al. Retardation of post-natal development caused by a negatively acting thyroid hormone receptor α1. EMBO Journal 2002 21 5079-5087. (doi:10.1093/emboj/cdf523)
16. Bassett JH, O'Shea PJ, Sriskantharajah S, Rabier B, Boyde A, Howell PG, Weiss RE, Roux JP, Malaval L, Clement-Lacroix P et al. Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Molecular Endocrinology 2007 21 1095-1107. (doi:10.1210/me.2007-0033)
17. Bassett JH, Boyde A, Howell PG, Bassett RH, Galliford TM, Archanco M, Evans H, Lawson MA, Croucher P, St Germain DL et al. Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. PNAS 2010 107 7604-7609. (doi:10.1073/pnas.0911346107)
18. Murphy E, Gluer CC, Reid DM, Felsenberg D, Roux C, Eastell R & Williams GR. Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2010 95 3173-3181. (doi:10.1210/jc.2009-2630)
19. Gluer CC, Eastell R, Reid DM, Felsenberg D, Roux C, Barkmann R, Timm W, Blenk T, Armbrecht G, Stewart A et al. Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. Journal of Bone and Mineral Research 2004 19 782-793. (doi:10.1359/jbmr.040304)
20. Medici M, Ikram MA, Van Der Lijn F, Den Heijer T, Vernooij MW, Hofman A, Niessen WJ, Visser TJ, Breteler MM & Peeters RP. The thyroid hormone receptor α locus and white matter lesions: a role for the clock gene REV-ERBα. Thyroid 2012 22 1181-1186. (doi:10.1089/thy.2012.0198)
21. Medici M, Rivadeneira F, Van Der Deure WM, Hofman A, Van Meurs JB, Styrkarsdottir U, Van Duijn CM, Spector T, Kiel DP, Uitterlinden AG et al. A large-scale population-based analysis of common genetic variation in the thyroid hormone receptor a locus and bone. Thyroid 2012 22 223-224. (doi:10.1089/thy.2011.0245)
22. Grarup N, Andersen MK, Andreasen CH, Albrechtsen A, Borch-Johnsen K, Jorgensen T, Auwerx J, Schmitz O, Hansen T & Pedersen O. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. Journal of Clinical Endocrinology and Metabolism 2007 92 363-366. (doi:10.1210/jc.2006-1958)
23. Meulenbelt I, Min JL, Bos S, Riyazi N, Houwing-Duistermaat JJ, Van Der Wijk HJ, Kroon HM, Nakajima M, Ikegawa S, Uitterlinden AG et al. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Human Molecular Genetics 2008 17 1867-1875. (doi:10.1093/hmg/ddn082)
24. Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM & Dayan CM. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. Journal of Clinical Endocrinology and Metabolism 2009 94 1623-1629.
25. Yerges LM, Klei L, Cauley JA, Roeder K, Kammerer CM, Ensrud KE, Nestlerode CS, Lewis C, Lang TF, Barrett-Connor E et al. Candidate gene analysis of femoral neck trabecular and cortical volumetric bone mineral density in older men. Journal of Bone and Mineral Research 2010 25 330-338. (doi:10.1359/jbmr.090729)
26. Yerges LM, Klei L, Cauley JA, Roeder K, Kammerer CM, Moffett SP, Ensrud KE, Nestlerode CS, Marshall LM, Hoffman AR et al. High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men. Journal of Bone and Mineral Research 2009 24 2039-2049. (doi:10.1359/jbmr.090524)
27. Ralston SH & Uitterlinden AG. Genetics of osteoporosis. Endocrine Reviews 2010 31 629-662. (doi:10.1210/er.2009-0044)
28. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE, Oei L, Albagha OM, Amin N, Kemp JP et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature Genetics 2012 44 491-501. (doi:10.1038/ng.2249)
29. Medina-Gomez C, Kemp JP, Estrada K, Eriksson J, Liu J, Reppe S, Evans DM, Heppe DH, Vandenput L, Herrera L et al. Meta-analysis of genome-wide scans for total body BMD in children and adults reveals allelic heterogeneity and age-specific effects at the WNT16 locus. PLoS Genetics 2012 8 e1002718. (doi:10.1371/journal.pgen. 1002718)
30. Zhang L, Choi HJ, Estrada K, Leo PJ, Li J, Pei YF, Zhang Y, Lin Y, Shen H, Liu YZ et al. Multi-stage genome-wide association meta-analyses identified two new loci for bone mineral density. Human Molecular Genetics 2014. In press. (doi:10.1093/hmg/ddt575)
31. Manolio TA & Collins FS. The HapMap and genome-wide association studies in diagnosis and therapy. Annual Review of Medicine 2009 60 443-456. (doi:10.1146/annurev. med.60.061907.093117)
32. Visscher PM, Brown MA, McCarthy MI & Yang J. Five years of GWAS discovery. American Journal of Human Genetics 2012 90 7-24. (doi:10.1016/j.ajhg. 2011.11.029)
33. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA & O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. New England Journal of Medicine 1999 341 879-884. (doi:10.1056/NEJM199909163411204)
34. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations. New England Journal of Medicine 2006 355 467-477. (doi:10.1056/NEJMoa061759)
35. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Boriraj VV et al. Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature 1996 384 455-458. (doi:10.1038/384455a0)